Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Philips Foundation announced its 2021 Annual Report showcasing its mission to provide quality healthcare to underserved communities. Over 17 million people benefited from 24 projects in collaboration with NGOs and community groups, doubling the previous year's figure. The foundation launched a new social impact investment vehicle to support early-stage social enterprises. It also initiated disaster relief efforts in response to the COVID-19 pandemic and the Ukraine crisis, reflecting its commitment to sustainable healthcare solutions for vulnerable populations.
Royal Philips (NYSE: PHG) is showcasing its innovations at EuroPCR 2022, enabling ultra-low contrast percutaneous coronary intervention (ULC-PCI). These solutions enhance procedure planning and patient safety by co-registering intravascular ultrasound and physiological assessment data onto angiograms, reducing iodinated contrast media use. This is particularly beneficial for patients at risk of acute kidney injury. The company aims to improve outcomes for complex patients through advanced imaging technologies, allowing for safer, more effective coronary interventions.
Royal Philips (NYSE: PHG) announced the international launch of EchoNavigator 4.0 at EuroPCR 2022. This advanced image-guided therapy solution enhances minimally-invasive treatment for structural heart disease by integrating real-time echocardiography and X-ray imaging. Key features include 3D anatomical modeling and transseptal puncture guidance, improving procedural confidence and precision. The product aims to address the rising demand for effective cardiovascular care amidst staffing shortages, ultimately supporting better patient outcomes.
Royal Philips announced the approval of a EUR 0.85 per share dividend at its 2022 AGM, reflecting its commitment to shareholder returns. The company appointed Herna Verhagen and Sanjay Poonen as new Supervisory Board members, while Paul Stoffels and Marc Harrison were re-appointed. The Advisory vote on the 2021 Remuneration Report has been noted, with Philips promising to engage with shareholder feedback for future reports. Other approvals included Ernst & Young as the auditor and the adoption of financial statements.
Royal Philips (NYSE: PHG) has received FDA 510(k) clearance for its new MR 7700 3.0T MR system, designed to enhance diagnostic imaging with exceptional performance and precision.
The system integrates AI features to streamline workflows, providing clinicians with capabilities to image multiple nuclei efficiently. Key benefits include up to 35% shorter scan times and improved signal-to-noise ratios, translating to enhanced patient care and lower operational costs.
Philips showcases the MR 7700 at the ISMRM annual meeting and focuses on its multi-nuclei capabilities to improve clinical pathways.
KONINKLIJKE PHILIPS N.V. has announced the results of its tender offers for its existing Euro Notes amounting to €1.5 billion. Valid offers were received for the 2023, 2024, and 2025 Euro Notes, with total amounts of €196.98 million, €224.54 million, and €154.47 million respectively. The company will accept these offers at prices above par, leading to a total settlement on May 10, 2022. Remaining outstanding amounts post-settlement include €303.02 million for the 2023 Notes and €275.47 million for the 2024 Notes, both of which are slated for redemption.
KONINKLIJKE PHILIPS N.V. announced the results of its tender offers for its outstanding Euro notes, with a total of €196,976,000 in 2023 Euro Notes, €224,535,000 in 2024 Euro Notes, and €154,471,000 in 2025 Euro Notes validly tendered. The company intends to accept all validly tendered Existing Notes without pro-ration. The maximum acceptance amount for the offers is set at €230,193,677.02. Settlement is expected on 10 May 2022. Existing Notes not accepted will remain outstanding, and the company plans to redeem them post-settlement.
Royal Philips announced the results of its tender offer for its outstanding debentures. As of the May 5, 2022 expiration time, approximately $20.86 million in aggregate principal amount was validly tendered and not withdrawn. No notes were tendered under guaranteed delivery procedures. The settlement date for accepted notes is expected to be May 10, 2022, with holders receiving accrued interest. The offer impacts the 2025 Series A, 2025 Series B, and 2026 Notes, with specific principal amounts tendered detailed in the release.
Royal Philips has announced the pricing terms for its cash tender offer to purchase its outstanding 71/8% Series A Debentures, 73/4% Series B Debentures, and 7.200% Notes. The final deadline for holders to tender their notes is 5:00 p.m., New York City time, on May 5, 2022. Accepted holders will receive applicable consideration plus accrued interest. The offer is subject to financing conditions, with settlement expected on May 10, 2022.
Royal Philips (NYSE: PHG) is showcasing its integrated solutions for stroke care at the ESOC 2022 conference, aimed at enhancing diagnostic confidence and reducing treatment time. The company emphasizes the urgent need for optimized workflows in stroke care, as timely treatment is vital for patient outcomes. Key offerings include advanced imaging technologies like the Spectral CT 7500 and ePatch for continuous ECG monitoring. Philips is also sponsoring the WE-TRUST trial to compare traditional and Direct to Angio Suite approaches in stroke treatment, which aims to lower costs and minimize disability.